Publication | Open Access

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Hematological MalignancyNeuro-oncologyTreatment StrategiesMedicineStandard Temozolomide TherapyClinical TrialsNeurologyHigh-grade GliomasCancer TreatmentRadiation OncologyOncologyGliomaNovel TherapyMethylated Mgmt PromoterLomustine-temozolomide Combination TherapyHealth Sciences